GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Beneish M-Score
中文

Xtant Medical Holdings (Xtant Medical Holdings) Beneish M-Score : -1.14 (As of Apr. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.14 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Xtant Medical Holdings's Beneish M-Score or its related term are showing as below:

XTNT' s Beneish M-Score Range Over the Past 10 Years
Min: -4.98   Med: -3.01   Max: 0.61
Current: -1.14

During the past 13 years, the highest Beneish M-Score of Xtant Medical Holdings was 0.61. The lowest was -4.98. And the median was -3.01.


Xtant Medical Holdings Beneish M-Score Historical Data

The historical data trend for Xtant Medical Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Beneish M-Score Chart

Xtant Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.31 -3.23 -2.79 -2.28 -1.14

Xtant Medical Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.28 -0.90 -0.97 -0.97 -1.14

Competitive Comparison of Xtant Medical Holdings's Beneish M-Score

For the Medical Devices subindustry, Xtant Medical Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Beneish M-Score falls into.



Xtant Medical Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Xtant Medical Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2128+0.528 * 0.9126+0.404 * 3.043+0.892 * 1.575+0.115 * 0.6444
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0748+4.679 * -0.018734-0.327 * 1.024
=-1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $20.73 Mil.
Revenue was 28.108 + 25.019 + 20.232 + 17.943 = $91.30 Mil.
Gross Profit was 17.137 + 15.334 + 12.459 + 10.536 = $55.47 Mil.
Total Current Assets was $64.87 Mil.
Total Assets was $92.61 Mil.
Property, Plant and Equipment(Net PPE) was $10.22 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.17 Mil.
Selling, General, & Admin. Expense(SGA) was $64.29 Mil.
Total Current Liabilities was $22.99 Mil.
Long-Term Debt & Capital Lease Obligation was $18.04 Mil.
Net Income was -4.303 + 9.231 + -2.19 + -2.078 = $0.66 Mil.
Non Operating Income was 0.882 + 11.028 + 0 + 0 = $11.91 Mil.
Cash Flow from Operations was -0.915 + -3.834 + -2.521 + -2.245 = $-9.52 Mil.
Total Receivables was $10.85 Mil.
Revenue was 15.27 + 14.462 + 15.277 + 12.959 = $57.97 Mil.
Gross Profit was 8.306 + 7.896 + 8.374 + 7.56 = $32.14 Mil.
Total Current Assets was $49.32 Mil.
Total Assets was $60.23 Mil.
Property, Plant and Equipment(Net PPE) was $7.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.29 Mil.
Selling, General, & Admin. Expense(SGA) was $37.98 Mil.
Total Current Liabilities was $15.22 Mil.
Long-Term Debt & Capital Lease Obligation was $10.84 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(20.731 / 91.302) / (10.853 / 57.968)
=0.22706 / 0.187224
=1.2128

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(32.136 / 57.968) / (55.466 / 91.302)
=0.554375 / 0.6075
=0.9126

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (64.869 + 10.215) / 92.612) / (1 - (49.318 + 7.165) / 60.229)
=0.189263 / 0.062196
=3.043

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=91.302 / 57.968
=1.575

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.292 / (1.292 + 7.165)) / (3.174 / (3.174 + 10.215))
=0.152773 / 0.23706
=0.6444

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(64.288 / 91.302) / (37.976 / 57.968)
=0.704125 / 0.65512
=1.0748

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.042 + 22.99) / 92.612) / ((10.84 + 15.218) / 60.229)
=0.443053 / 0.432649
=1.024

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.66 - 11.91 - -9.515) / 92.612
=-0.018734

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Xtant Medical Holdings has a M-score of -1.14 signals that the company is likely to be a manipulator.


Xtant Medical Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Executives
Kevin D Brandt officer: VP & Chief Commercial Officer 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller director 664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson director 664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils officer: Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger officer: Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne officer: President and CEO 664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis director 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen officer: VP, Finance and Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin officer: VP & Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen officer: SVP Fiance & Admin. & CFO 664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750

Xtant Medical Holdings (Xtant Medical Holdings) Headlines

From GuruFocus